Curanex Pharmaceuticals, a preclinical biopharma developing botanical-based treatments for various diseases, filed on Wednesday with the SEC to raise up to $10 million in an initial public offering.
The company filed to offer 2 million shares at a price range of $4 to $6. At the proposed midpoint, Curanex would command a fully diluted market value of $210 million.
Curanex is developing its lead drug candidate, Phyto-N, which is a proprietary botanical extract with chemical components and pharmacological activities which enhance its anti-inflammatory properties. With an active ingredient derived from traditional Chinese medicine, Curanex plans to submit an IND to begin trials of Phyto-N in 2025. The company also plans to pursue Phyto-N in atopic dermatitis, diabetes, nonalcoholic fatty liver disease (NAFLD), gout, and acne.
The Jericho, NY-based company was founded in 2018 and plans to list on the Nasdaq under the symbol CURX. Dominari Securities and Revere Securities are the joint bookrunners on the deal.
Preclinical biopharma Curanex Pharmaceuticals files for a $10 million IPO
October 16, 2024

